Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccines Chess Game Continues With Baxter Sale To Pfizer

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.

You may also be interested in...



Novartis CEO Shrugs Off Paltry Price For Flu Vaccines Unit

Novartis says the $275 million received from Australia’s CSL for its influenza unit was not a great price but was “the best” on offer, allowing the Swiss group to fully exit vaccines and continue moving ahead on its strategic plan.

Same-Day BLA Filings Show Pfizer Has Gained Ground On Novartis In Meningitis B

Both companies have “breakthrough” therapy designations from FDA and both announced BLA filings on June 17, but Pfizer’s earlier completion of the rolling submission could give it an edge in the race to launch a meningitis B vaccine in the U.S.

Bigger And Smaller? Pfizer Pursues AstraZeneca But Hasn’t Given Up On A Split

A Pfizer break up is still an option even if the company completes a mega-merger with AstraZeneca, CEO Ian Read said May 5. The company’s first quarter sales and earnings results highlighted how important completing a transaction could be for the company, with sales down 9% and earnings down 15%.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077513

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel